HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.

AuthorsFranck E Nicolini, H Jean Khoury, Luke Akard, Delphine Rea, Hagop Kantarjian, Michele Baccarani, Janis Leonoudakis, Adam Craig, Annie-Claude Benichou, Jorge Cortes
JournalHaematologica (Haematologica) Vol. 98 Issue 7 Pg. e78-9 (Jul 2013) ISSN: 1592-8721 [Electronic] Italy
PMID23753022 (Publication Type: Letter)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Harringtonines
  • Protein Kinase Inhibitors
  • Homoharringtonine
  • Protein-Tyrosine Kinases
Topics
  • Antineoplastic Agents, Phytogenic (pharmacology, therapeutic use)
  • Drug Resistance, Neoplasm (drug effects, physiology)
  • Follow-Up Studies
  • Harringtonines (pharmacology, therapeutic use)
  • Homoharringtonine
  • Humans
  • Leukemia, Myeloid, Accelerated Phase (drug therapy, enzymology, mortality)
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • Protein-Tyrosine Kinases (antagonists & inhibitors, metabolism)
  • Survival Rate (trends)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: